10.1016/j.amjcard.2007.05.022
Combination therapies Combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists offers a promising approach to enhance cardiovascular and kidney protection in people with type 2 diabetes mellitus, particularly those at high risk [9,20]
However, there were non-significant trends toward lower BMI (MD: -1.21, 95% CI [-2.66, 0.25], p= 0.10), body weight (MD: -3.00, 95% CI [-7.03, 1.04], p= 0.15), waist circumference (MD: -3.18, 95% CI [-7.77, 1.41], p= 0.17), diastolic blood pressure (MD: -4.07, 95% CI [-12.25, 4.12], p= 0.33), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (MD: -0.08, 95% CI [-1.10, 0.95], p= 0.89), AST (MD: -4.77, 95% CI [-10.74, 1.20], p= 0.12)., and ALT levels (MD: -4.28, 95% CI [-10.53, 1.97], p= 0.18) without reaching statistical significance
Box: Glucagon-like peptide-1 receptor agonists affected by supply issues Semaglutide: Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5mg solution for injection in pre-filled pen Ozempic 1mg solution for injection in pre-filled pen Rybelsus 3mg tablets Rybelsus 7mg tablets Rybelsus 14mg tablets Dulaglutide: Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen Trulicity 3 mg solution for injection in pre-filled pen Trulicity 4.5 mg solution for injection in pre-filled pen Liraglutide: Victoza 6mg/mL solution for injection in pre-filled pen Saxenda 6mg/mL solution for injection in pre-filled pen Exenatide: Byetta 5 micrograms/0.02mL solution for injection 1.2ml pre-filled pens Byetta 10 micrograms/0.04mL solution for injection 1.2ml pre-filled pens Bydureon 2mg/0.85mL prolonged-release suspension for injection 1.2mL pre-filled pens You must be logged in to post a comment.
Serotonin syndrome
